Consolidated Statements of (Deficit) Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]	Series B Preferred Stock [Member]	Total
Balance at Dec. 31, 2017	$ 4	$ 192,670	$ (194,170)	$ (1,914)	$ 0	$ (3,410)
Balance (in shares) at Dec. 31, 2017	3,671,014				0
Stock-based compensation	$ 0	2,074	0	0	$ 0	2,074
Stock issued under "at-the-market" offering	$ 3	12,169	0	0	0	12,172
Stock issued under "at-the-market" offering (in shares)	3,534,982
Common stock and warrants issued to vendors	$ 0	35	0	0	0	35
Common stock and warrants issued to vendors (in Shares)	50,000
Series A Preferred Stock Dividends	$ 0	0	(243)	0	$ 0	(243)
Stock issued for exercise of stock options (in shares)					0
Series B preferred stock beneficial conversion feature discount	0	0	(9,161)	0	$ 9,161	0
Issuance of Common Stock, preferred Stock and Warrants in Units Offering, net of issuance costs	$ 2	16,273	0	0	$ 641	16,916
Issuance of Common Stock, preferred Stock and Warrants in Units Offering, net of issuance costs (in shares)	2,520,000				15,723
Issuance of SYN Biomics Stock	$ 0	977	0	(941)	$ 0	36
Conversion of Series B Preferred Stock to Common	$ 6	6,556	(2,520)	0	$ (4,042)	0
Conversion of Series B Preferred Stock to Common (in shares)	5,706,087				(6,562)
Net loss	$ 0	0	(13,367)	0	$ 0	(13,367)
Non-controlling interest	0	0	0	(54)	0	(54)
Balance at Dec. 31, 2018	$ 15	230,754	(219,461)	(2,909)	$ 5,760	14,159
Balance (in shares) at Dec. 31, 2018	15,482,083				9,161
Stock-based compensation	$ 0	340	0	0	$ 0	340
Series A Preferred Stock Dividends	0	0	(248)	0	0	(248)
Issuance of SYN Biomics Stock	0	(36)	0	108	0	72
Conversion of Series B Preferred Stock to Common	$ 2	1,522	(525)	0	$ (999)	0
Conversion of Series B Preferred Stock to Common (in shares)	1,324,347				(1,523)
Net loss	$ 0	0	(15,303)	0	$ 0	(15,303)
Non-controlling interest	0	0	0	(77)	0	(77)
Balance at Dec. 31, 2019	$ 17	$ 232,580	$ (235,537)	$ (2,878)	$ 4,761	$ (1,057)
Balance (in shares) at Dec. 31, 2019	16,806,430				7,638